1. Report Overview

1.1 Biologics Overview

1.2 Why you Should Read this Report

1.3 How this Report Delivers

1.4 Main Questions Answered by this Report

1.5 Who is this Report for?

1.6 Research and Analysis Methods

1.7 Frequently Asked Questions (FAQ)

1.8 Some Associated Reports

1.9 About Visiongain

2. Introduction to the Biologics Market and Key Concepts

2.1 Biologics: Large and Complex Products

2.2 A Brief History of Biological Drug Development

2.3 Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?

2.4 What are Biosimilars?

2.4.1 Brief History of Biosimilars

2.4.2 What are Interchangeable Biological Products and how do They Differ from Biosimilars?

2.4.3 Why Many Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars

2.5 Marginal Cases

2.6 Vaccines Market

3. The Global Biologics Market to 2027

3.1 The Global Biologics Market Forecast, to 2027

3.2 What Factors Will Drive Growth in the Biologics Market?

3.3 Ageing Population and the Rise of Chronic Disease

3.4 Eight of the Top Ten Best-Selling Drugs in 2015 were Biologics

3.5 Biologics Constitute 19% of the Global Pharmaceutical Market - Further Launches Will Drive Market

3.6 Biosimilars - Both an Opportunity and a Threat

3.7 What Factors Will Restrain Growth in the Biologics Market?

3.8 High Costs in the Face of Declining National Healthcare Budgets

3.9 In Some Areas, Clinical Efficacy is not Superior Enough to Justify the Price Gap

3.10 Over $67bn worth of Biologic Patents due to Expire by 2020

3.11 Administration is Often not as Convenient

3.12 Biologics Market: Submarket Forecasts to 2027

4. Protein Therapeutics Submarket to 2027

4.1 Largest and Most Diverse Submarket

4.2 Proteins have been used Medicinally since the 19th Century

4.2.1 Recombinant DNA Technology - The Major Breakthrough in the use of Protein Drugs

4.3 Protein Therapeutics Submarket Forecast to 2027

4.4 Insulin Submarket to 2027

4.4.1 The First Protein Therapeutic

4.4.2 430 Million People Expected to be Diagnosed with Diabetes by 2030

4.4.3 The Status of the Market in 2016: Novo Nordisk, Sanofi and Eli Lilly Dominate

4.4.4 Insulin Submarket Forecast to 2027

4.4.5 Lantus: The Market Leading Drug by Far

4.4.5.1 Lantus Revenue Forecast to 2027

4.4.6 NovoLog/NovoRapid Revenue Forecast to 2027

4.4.7 Humalog Revenue Forecast to 2027

4.4.8 New Approvals and Pipeline

4.4.8.1 Tresiba (Novo Nordisk)

4.4.8.2 BIOD-123 (Biodel)

4.5 Biosimilar Insulin

4.5.1 Approved Insulin Biosimilars

4.5.2 Abasaglar/Basaglar/Insulin Glargine BS - The First Insulin Biosimilars to be Approved in Developed Markets. Delayed in the US

4.6 Other Recombinant Hormones: Erythropoietins, G-CSF and Human Growth Hormone

4.6.1 Erythropoietin

4.6.2 First-Generation Therapies Launched in the 1980s

4.6.2.1 Aranesp: Slowly Growing

4.6.2.2 Epogen: Increases in Selling Price are No Longer Enough to Ward off Decline

4.6.2.3 Procrit/Eprex: In Decline Since 2013

4.6.2.4 NeoRecormon and Mircera (Roche) Provides Competition for Market Leader Amgen

4.6.2.5 Safety Concerns for Erythropoietin-Stimulating Agents is Leading to Decreased Demand

4.6.2.6 The Challenge from Oral Therapies is Coming

4.6.2.7 Treating Anaemia in Patients with CKD - The Leading Use of EPO Therapies

4.6.2.8 Many Biosimilar Epoetins Approved Around the World

4.6.3 G-CSF

4.6.4 G-CSF: Discovered 1983. Recombinant Forms Available Since 1991

4.6.4.1 Amgen Leads the Market

4.6.4.2 Neupogen and Neulasta Revenues, and the Onpro Kit

4.6.4.3 Teva Aiming to Challenge Amgen’s Dominance

4.6.4.4 Facing Much Biosimilar Competition Around the World

4.6.5 Human Growth Hormone

4.6.5.1 Human Growth Hormone: First Extracted in 1958

4.6.5.2 Novo Nordisk Dominates Market

4.6.5.3 Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate

4.6.5.4 Multiple Biosimilars Available - Omnitrope is Market Leader

4.6.5.5 Biosimilar Growth Hormones in Asia

4.6.6 Other Recombinant Hormones Submarket Forecast to 2027

4.7 Plasma and Recombinant Coagulating Factors

4.7.1 Discovery of Plasma and Clotting Proteins

4.7.2 Types of Recombinant Factor

4.7.3 Clotting Factor Deficiency Diseases

4.7.4 Baxter/Baxalta: Entered the Bleeding Disorders Market in 1992, Markets Various Leading Products

4.7.4.1 Baxter: New Product Launches Include Rixubis and Obizur

4.7.5 Novo Nordisk: Committed to Remaining a Leading Company in the Bleeding Disorders Market

4.7.5.1 Novo Nordisk: Has filed for Approval for N9-GP and NovoEight is Doing Well

4.7.6 Bayer: Markets Kogenate, Kogenate FS, and has Received FDA Approval for Kovaltry

4.7.7 Limited Opportunities for Biosimilar Challenge

4.7.8 Plasma and Recombinant Coagulating Factors Submarket Forecast to 2027

4.8 Interferons

4.8.1 Interferons: Key Antiviral and MS Therapies Since the 1990s

4.8.2 Interferons for Treating Hepatitis: Its Influence is Decreasing

4.8.3 Competition from Oral Protease and Polymerase Inhibitors

4.8.3.1 Oral Therapies are Expensive

4.8.4 Avonex: The Leading Interferon Therapy

4.8.4.1 Avonex Revenue Forecast to 2027

4.8.5 Rebif: Merck Attempting to Differentiate Rebif from Other Interferon Therapies

4.8.5.1 Rebif Revenue Forecast to 2027

4.8.6 Betaseron

4.8.7 Plegridy: New Therapy with High Potential

4.8.8 Biosimilar Interferons: None Approved in Developed Markets, but Many Available in Emerging Nations

4.8.9 Interferon Submarket Forecast to 2027

4.9 Enzyme Replacement and Other Protein Therapies Submarket

4.9.1 Cerezyme: Genzyme’s Leading Enzyme Replacement Therapy

4.9.2 Myozyme and Lumizyme

4.9.3 Fabrazyme and Aldurazyme

4.9.4 Botulinum Toxin Brands Include Botox, Dysport and Xeomin

4.9.5 Other Protein Therapeutics Pipeline

4.9.5.1 Anthera Buys Sollpura from Eli Lilly, Phase 3 Results Expected Q4 2016

4.9.5.2 Multikine (CEL-SCI)

4.9.5.3 Vonapantiase (Proteon Therapeutics)

4.9.6 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast to 2027

5. Monoclonal Antibodies Submarket to 2027

5.1 Monoclonal Antibodies Submarket: Scientific and Historical Background

5.1.1 Natural Antibodies: Key to the Immune System

5.1.2 From Serum Therapy to Monoclonal Antibodies

5.1.3 Humanising the mAb

5.1.4 MAbs have found Success in Treating Autoimmune Disorders, Cancers and Others Diseases - Great Potential for the Future

5.1.5 MAbs for All? Technologies Come Off Patent

5.2 Three out of the Top Five Best-Selling Drugs are mAbs

5.3 Autoimmune mAbs

5.3.1 Past Approvals

5.3.2 Humira - The World’s Best-Selling Prescription Drug

5.3.2.1 AbbVie Plans to Drive Growth Through New Indications

5.3.2.2 Positive Opinion from CHMP for Treatment of Non-Infectious Uveitis

5.3.2.3 Recently Approved for Hidradenitis Suppurativa in the US, Europe, and Japan

5.3.2.4 Biosimilar Adalimumab: Patents Protect Humira in Developed Markets for Now

5.3.2.5 Humira Revenue Forecast to 2027

5.3.3 Remicade: Second Only to Humira

5.3.4 2016 Revenue for J&J and Merck

5.3.4.1 Has Defended Revenues well but now Has to Deal with Biosimilar Competition

5.3.4.2 Patent Dance in US

5.3.4.3 Biosimilar Infliximab: Multiple Launches

5.3.4.4 Remicade Revenue Forecast to 2027

5.3.5 Stelara: Blockbuster Status Well Established

5.3.5.1 Stelara Revenues 2014-2016

5.3.5.2 Orphan Drug Designation for paediatric Crohn’s Disease

5.3.6 Simponi and Simponi Aria: Another Blockbuster mAb for J&J and Merck & Co.

5.3.6.1 2015 and 2014 Revenue Breakdown

5.3.7 Tysabri: Blockbuster Drug’s High Efficacy Offsets its Risks

5.3.7.1 Tysabri: Revenues 2012-2016

5.3.7.2 Tysabri Revenue Forecast to 2027

5.3.8 Xolair: New Indication, and Revenue Breakdown

5.3.9 Actemra/RoActemra: Strong Growth in All Regions

5.3.10 Cimzia: Blockbuster Which has been Used by Over 90,000 Patients

5.3.11 Autoimmune mAbs Pipeline: RA is the Main Target

5.3.11.1 Sarilumab (REGN88/SAR153191) by Regeneron and Sanofi: BLA Accepted for Review and Decision Expected by November 2016

5.3.11.2 Sirukumab (CNTO-136) by J&J and GSK: Multiple Phase 3 Studies Around the World

5.3.11.3 Clazakizumab: Developed by Alder Biopharmaceuticals and BMS but now Licensed to Vitaeris

5.3.11.4 Tregalizumab (BT-061) by Biotest: AbbVie Backs out After Poor Results

5.3.11.5 Mavrilimumab by AstraZeneca: Approaching Phase 3

5.3.11.6 Zinbryta (daclizumab high-yield process) by Biogen and AbbVie: Positive Opinion from CHMP

5.3.11.7 Lebrikizumab by Roche: Undergoing Phase 3 After Positive Phase 2b Results

5.3.11.8 Sifalimumab (MEDI-545) by AstraZeneca: Hasn’t Made the Cut for Phase 3

5.3.11.9 Anifrolumab by AstraZeneca

5.4 Oncology mAbs

5.4.1 Past Approvals

5.4.2 Rising Incidence of Cancer Will Drive Demand

5.4.3 Rituxan: The World’s Leading Anti-Cancer mAb

5.4.4 Biosimilar Rituximab: Two Candidates Await Approval in Europe

5.4.5 Gazyva: Roche’s Successor to Rituxan, Will Help to Retain Revenues in Face of Biosimilar Competition

5.4.5.1 Approval for Follicular Lymphoma and Being Investigated for Other Indications

5.4.6 Avastin: Growing under CER, Through New Indications

5.4.6.1 Controversy over Off-Label Avastin use: Roche is Backed up by Incidents in India, and Opinion of EFPIA

5.4.6.2 Biosimilar Bevacizumab: Late Patent Expiry is a Blessing for Roche, Although Various Biosimilars in Development

5.4.7 Herceptin: Breast Cancer Blockbuster

5.4.7.1 Pricing Challenges in Emerging Markets, and 2016 Revenues

5.4.7.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin

5.4.7.3 Herceptin Revenue Forecast to 2027

5.4.7.4 Biosimilar Trastuzumab

5.4.8 Kadcyla

5.4.8.1 Mixed Results from Different Clinical Trials

5.4.8.2 Kadcyla Sales Forecast to 2027

5.4.9 Perjeta

5.4.9.1 Positive Results from Different Clinical Trials

5.4.9.2 Perjeta Revenue Forecast to 2027

5.4.10 Yervoy: Bristol-Myers Squibb’s Leading Anti-Cancer mAb, KeepsHigh Revenues, but with Decline over 2015

5.4.11 Opdivo: Big Potential for Bristol-Myer Squibb’s PD-1 Inhibitor

5.4.11.1 Good News and Bad News for NSCLC from CheckMate Trials

5.4.11.2 Cyramza (Eli Lilly): Approved in Three Additional Indications Since its First Approval in April 2014

5.4.12 Oncology mAbs: New Approvals and Pipeline

5.4.12.1 Empliciti (Elotuzumab) by Bristol-Myers Squibb and AbbVie): Recently Approved

5.4.12.2 Avelumab: Pfizer and Merck KGaA Team Up to Develop Their Own Anti-PD mAb

5.4.12.3 Unituxin (United Therapeutics) Receives FDA Approval March 2015

5.4.12.4 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)

5.5 Monoclonal Antibodies Submarket Forecast to 2027

6. Fusion Proteins Submarket to 2027

6.1 Scientific and Historical Background

6.2 Differentiating Fusion Proteins

6.3 Enbrel: The First FP to be Approved, in 1998

6.3.1 Gradually Approved for Additional Indications

6.3.2 The Leading Fusion Protein

6.3.3 Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU

6.3.4 Multiple Biosimilars Available in Emerging Markets

6.3.5 Enbrel Revenue Forecast to 2027

6.4 Eylea: Blockbuster FP Treatment for Wet AMD

6.4.1 Eylea Revenue Forecast to 2027

6.5 Orencia: Grows Blockbuster Revenues for Second Year in a Row

6.6 Nplate: Generates Half a Billion in Revenues for Amgen

6.7 Eloctate: Approved June 2014, Fulfils Unmet Need in the Haemophilia Community

6.8 Nulojix: Bristol-Myers Squibb’s Therapy for Preventing Organ Rejection

6.9 Arcalyst by Regeneron Pharmaceuticals: For Very Rare Conditions

6.10 Fusion Proteins Pipeline

6.10.1 Trebananib (Amgen)

6.10.2 Sotatercept by Acceleron Pharma and Celgene Corporation - Currently Undergoing Eight Clinical Trials

6.10.3 Blisibimod (Anthera Pharmaceuticals) for the Treatment of Various Autoimmune Diseases, in Late Stage Development

6.11 Fusion Protein Submarket Forecast to 2027

7. Regenerative Medicines Submarket to 2027

7.1 Regenerative Medicines Market Breakdown

7.2 Regenerative Medicines Submarket Forecast, to 2027

7.3 Stem Cell Therapies Submarket, to 2027

7.3.1 Stem Cells: Scientific Breakdown

7.3.2 Stem Cell Therapies Submarket Breakdown

7.3.3 Haematopoietic Stem Cell Transplantation: Over 95,000 Carried out in 2016

7.3.3.1 From Procedures to Products: Cord Blood Stem Cell Approvals

7.3.4 Osteocel Plus: The Leading Stem Cell Orthobiologic

7.3.4.1 Osteocel Plus Revenue Forecast to 2027

7.3.5 Trinity Evolution and Trinity Elite

7.3.5.1 Trinity Evolution and Trinity Elite Revenue Forecast to 2027

7.3.6 MSC-100-IV (Previously Known as Prochymal): World’s First Approved Stem Cell Drug Outside of South Korea

7.3.6.1 An Important Role to Play in the Future of HSCT, and also Wins Approval in Japan through Partner

7.3.7 CARTISTEM (MEDIPOST): The World’s First Allogeneic Stem Cell Drug

7.3.8 Hearticellgram-AMI (PharmaCell B.V.): One of the First Approved Cardiovascular Stem Cell Treatments in the World

7.3.9 Stem Cell Therapies Pipeline

7.3.9.1 Cx601 by TiGenix: Marketing Authorisation Application has been Submitted to EMA

7.3.9.2 CardiAMP (BioCardia) for Heart Failure: Undergoing Phase 3 Trial and has Received Grant from MSCRF

7.3.9.3 NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS in Phase 2 and Due to end Soon

7.3.9.4 Agenmestencel-T (Apceth): Phase 1/2 Due to end Soon

7.3.10 Stem Cell Therapies Submarket Forecast to 2027

7.4 Tissue Engineering Therapies Submarket to 2027

7.4.1 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes

7.4.2 Current Status of the Market

7.4.3 Apligraf: The Leading Product

7.4.3.1 Apligraf Revenue Forecast to 2027

7.4.4 Dermagraft: Organogenesis Further Strengthens Position Through this 2014 Acquisition

7.4.4.1 Dermagraft Revenue Forecast to 2027

7.4.5 ReCell

7.4.6 MySkin and CyroSkin

7.4.7 Tissue Engineering Therapies Pipeline

7.4.7.1 NeoCart by Histogenics: Undergoing Phase 3 Trial for Knee Cartilage Repair

7.4.7.2 Extracorporeal Bio-Artificial Liver Therapy by Vital Therapies

7.4.7.3 StrataGraft by Stratatech Corporation Demonstrates Positive Top-Line Results

7.4.8 Tissue Engineering Therapies Submarket Forecast to 2027

7.5 Gene Therapies Submarket to 2027

7.5.1 Gene Therapy: Historical and Scientific Background

7.5.2 Harnessing Infectivity: Viral Vectors in Gene Therapy

7.5.3 Approved Gene Therapy Products

7.5.3.1 Gendicine: The World’s First Commercial Gene Therapy Product

7.5.3.2 Oncorine: First Oncolytic Viral Therapy

7.5.3.3 Neovasculgen: Russia’s First Gene Therapy

7.5.3.4 Neovasculgen: Drop in Revenues in 2015, but HSCI Predicts Notable Increases as Product is Added to VED List

7.5.3.5 Glybera: The First Gene Therapy for Western Markets, Although Has Abandoned Hope of Receiving FDA-Approval

7.5.4 IMLYGIC

7.5.4.1 IMLYGIC: Clinical Trials and Development Efforts

7.5.4.2 IMLYGIC: Revenue Forecast to 2027

7.5.5 Gene Therapies Pipeline

7.5.5.1 AAV2-hRPE65v2 (Spark Therapeutics): Undergoing Phase 3 Trial

7.5.5.2 AdV-tk/ProstAtak (Advantagene): Phase 3

7.5.5.3 Collategene (beperminogene perplasmid, AMG0001) - (AnGes MG/Vical)

7.5.6 Gene Therapy Submarket Forecast to 2027

8. Leading National Markets for Biologics to 2027

8.1 Regional Forecasts for the Global Biologics Market to 2027

8.2 US Biologics Market to 2027

8.2.1 The Major National Market

8.2.2 Value-Based Pricing in the US

8.2.3 Regulation of Biologics in the US

8.2.4 US Biosimilars Market

8.2.4.1 FDA Finalises Biosimilar Guidelines and Biosimilar Naming

8.2.5 US Biologics Market Forecast to 2027

8.3 EU5 Biologics Market to 2027

8.3.1 Current Composition and Future Outlook

8.3.2 European Biosimilar Market

8.3.2.1 History of EMA Guidelines and Updates

8.3.3 EU5 Market Forecast by Nation to 2027

8.4 Japanese Biologics Market to 2027

8.4.1 Current Status of the Japanese Biologics Market

8.4.2 Japanese Biosimilar Market

8.4.3 Japanese Biologics Market Forecast to 2027

8.5 BRIC National Biologic Markets to 2027

8.5.1 BRIC Markets Overview

8.5.2 BRIC Biologic Market Forecast to 2027

8.5.2.1 Unique Challenges Faced by the Biologics Industry have led to Current Composition of the BRIC Biologic Market

8.5.2.2 Future Outlook

8.5.2.3 BRIC Nation Market Shares in the Global Biologics Market will Nearly Double During the Forecast Period

8.5.3 Brazil: Disproportionately High Government Spending on Biologics

8.5.3.1 Brazilian Government Eager to Promote Domestic Biologic and Biosimilar Development

8.5.4 Russia: Another Government Which is Eager to Increase Domestic Biological Drug Development

8.5.5 India: Biologics Market Behind that of Other BRIC Nations, but Biosimilars Submarket Thriving

8.5.5.1 CDSCO Guidelines Released in 2012

8.5.6 China: Expected to the Largest BRIC Market for Biologics by 2020

8.5.6.1 The Largest National Biosimilar Market in the World

9. Qualitative Analysis of the Biologics Market and Industry

9.1 SWOT Analysis of the Global Biologics Market and Industry

9.1.1 Strengths

9.1.2 Opportunities

9.1.3 Weaknesses

9.1.4 Threats

9.2 STEP Analysis of the Global Biologics Market and Industry

9.2.1 Social Factors

9.2.2 Technological Developments

9.2.3 Economic Pressures

9.2.4 Political Issues

10. Conclusions

10.1 Biologics Market to Achieve Steady Growth Throughout the Forecast Period

10.2 Changes in Market Composition: mAbs to Become Leading Submarket

10.3 The Emergence of Biosimilars

10.4 Challenges for the Market

Visiongain Report Sales Order Form

Some Associated Reports

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List of Figures

Figure 1.1 Forecasted Submarkets of the Biologics Market

Figure 3.1 Global Biologics Market Forecast: Revenues ($bn), to 2027

Figure 3.2 Submarkets within the Biologics Market Forecast: Revenues ($bn),2016-2027

Figure 4.1 Protein Therapeutics Submarket Forecast: Revenues ($bn), to 2027

Figure 4.2 Diabetes Prevalence in Leading National Markets, 2014

Figure 4.3 Insulin Submarket Forecast: Revenues ($bn), to 2027

Figure 4.4 Lantus Revenue Forecast: Revenues ($bn), to 2027

Figure 4.5 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn) to 2027

Figure 4.6 Humalog Revenue Forecast: Revenues ($bn), to 2027

Figure 4.7 Other Recombinant Hormones Submarket Forecast: Revenues ($bn),to 2027

Figure 4.8 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), to 2027

Figure 4.9 Avonex Submarket Forecast: Revenues ($bn), to 2027

Figure 4.10 Rebif Revenue Forecast: Revenue ($bn), to 2027

Figure 4.11 Interferon Submarket Forecast: Revenues ($bn), to 2027

Figure 4.12 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), to 2027

Figure 5.1 Humira Revenue Forecast: Revenue ($bn),to 2027

Figure 5.2 Remicade Revenue Forecast: Revenue ($bn),to 2027

Figure 5.3 Stelara Revenue 2014-2016: Revenue ($bn)

Figure 5.4 Total TysabriRevenues 2012-2016, Revenues ($m)

Figure 5.5 Tysabri Revenue Forecast: Revenue ($m), to 2027

Figure 5.6 Herceptin Revenue Forecast: Revenue ($bn),to 2027

Figure 5.7 Kadcyla Revenue Forecast: Revenue ($m), to 2027

Figure 5.8 Perjeta Revenue Forecast: Revenue ($bn), to 2027

Figure 5.9 Monoclonal Antibodies Submarket Forecast: Revenue ($bn),to 2027

Figure 6.1 Enbrel Revenue Forecast: Revenue ($bn), to 2027

Figure 6.2 Eylea Revenue Forecast: Revenue ($bn), to 2027

Figure 6.3 Fusion Proteins Forecast: Revenue ($bn), to 2027

Figure 7.1 Regenerative Medicines Market Forecast: Revenue ($bn), to 2027

Figure 7.2 Osteocel Plus Revenue Forecast: Revenue ($bn), to 2027

Figure 7.3 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), to 2027

Figure 7.4 Stem Cell Therapies Market Forecast: Revenue ($bn), to 2027

Figure 7.5 Apligraf Revenue Forecast: Revenue ($m), to 2027

Figure 7.6 Dermagraft Revenue Forecast: Revenue ($m),to 2027

Figure 7.7 Tissue Engineering Therapies Submarket: Revenues ($bn), to 2027

Figure 7.8 IMLYGIC Revenue Forecast: Revenue ($m), to 2027

Figure 7.9 Gene Therapies Market Forecast: Revenue ($bn), to 2027

Figure 8.1 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2016

Figure 8.2 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2027

Figure 8.3 Regional Forecasts for Global Biologics Market: Revenues ($bn),to 2027

Figure 8.4 US Biologics Market: Revenues ($bn),to 2027

Figure 8.5 EU5 Market Breakdown: Market Share (%), 2016

Figure 8.6 EU5 Biologics Market: Revenues ($bn), to 2027

Figure 8.7 Japanese Biologics Market: Revenues ($bn), to 2027

Figure 8.8 Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2016

Figure 8.9 BRIC Biologics Market: Revenues ($bn), to 2027

Figure 8.10 Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2027

Figure 9.1 SWOT Analysis of Biologics Market and Industry, to 2027

Figure 9.2 STEP Analysis of Biologics Market and Industry, to 2027

Figure 10.1 Global Biologics Market Forecast: Revenues ($bn), Annual Growth Rate (%), to 2027

Figure 10.2 Breakdown by Submarket: Revenues ($bn), to 2027

List of Tables

Table 1.1 Currency Exchange Rates: Average Exchange Rate to USD for 2015 and 2016

Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1993

Table 3.1 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 3.2 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%),2021-2026

Table 3.3 Top Ten Best-Selling Drugs in 2016: Revenue ($bn), Share of Biologics Market (%)

Table 3.4 Patent Status of Selected Leading Biologics

Table 3.5 Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2021

Table 3.6 Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2027

Table 4.1 First Approvals for Recombinant Protein Therapies,1982-1993

Table 4.2 Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.3 Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027

Table 4.4 Diabetes Prevalence in Leading National Markets, 2014

Table 4.5 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.6 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027

Table 4.7 Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.8 Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027

Table 4.9 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.10 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027

Table 4.11 Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2016-2021

Table 4.12 Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027

Table 4.13 Selected Insulin Biosimilars which have been Approved and Launched

Table 4.14 Selected EPO Biosimilars Approved in India

Table 4.15 European Biosimilar Approvals: G-CSF

Table 4.16 Selected Filgrastim Biosimilars Approved Worldwide, 2016

Table 4.17 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.18 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2027

Table 4.19 Selected Coagulating Factors Significant in Segment

Table 4.20 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.21 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027

Table 4.22 Selected Approved Branded Interferon Therapies

Table 4.23 Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.23 Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), to 2027

Table 4.25 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 4.26 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 4.27 Selected Interferon Alfa Biosimilars Approved Worldwide, 2016-2017

Table 4.28 Selected Interferon Beta Biosimilars Approved Worldwide,2016-2017

Table 4.29 Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.30 Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2022-2027

Table 4.31 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.32 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2022-2027

Table 5.1 Regions of an Antibody

Table 5.2 Natural Antibody Mechanisms of Action

Table 5.3 Top Five Best-Selling Drugs, 2016: Revenue ($bn)

Table 5.4 Selected Biosimilar Adalimumab Candidates

Table 5.5 Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 5.6 Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 5.7 Remicade 2016 Revenue Breakdown: Revenue ($bn), Percentage Change over 2016(%)

Table 5.8 Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021

Table 5.9 Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027

Table 5.10 Stelara Revenue 2014-2016:

Table 5.11 Total Tysabri Revenues 2012-2016, Revenues ($bn), AGR (%), CAGR (%)

Table 5.12 Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 5.13 Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 5.14 Xolair Revenue Breakdown (between Roche and Novartis): Revenue ($bn), AGR (%), 2015-2016

Table 5.15 Selected Ongoing Sirukumab (CNTO-136) Clinical Trials, 2016

Table 5.16 Selected Ongoing Lebrikizumab Clinical Trials, 2016

Table 5.17 Selected Ongoing Anifrolumab Clinical Trials, 2016

Table 5.18 Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021

Table 5.19 Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027

Table 5.20 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021

Table 5.21 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027

Table 5.22 Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 5.23 Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 5.24 FDA-Approved Indications for Cyramza

Table 5.25 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 5.26 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 6.1 Amgen’s US Patents and Expiry Dates for Enbrel

Table 6.1 Bristol-Myers Squibb’s pipeline developments for Orencia

Table 6.2 Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 6.3 Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027

Table 6.4 Eylea Revenue Breakdown 201: Regeneron and Bayer

Table 6.5 Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 6.6 Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 6.7 Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 6.8 Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 7.1 Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 7.2 Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 7.3 Potency and Source of Stem Cells

Table 7.4 Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 7.5 Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027

Table 7.6 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 7.7 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 7.8 Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021

Table 7.9 Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027

Table 7.10 Apligraf Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021

Table 7.11 Apligraf Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027

Table 7.12 Dermagraft Revenue Forecast: Revenue ($m), AGR (%), CAGR (%),2016-2021

Table 7.13 Dermagraft Revenue Forecast: Revenue ($m), AGR (%), CAGR (%),2022-2027

Table 7.14 Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), 2016-2021

Table 7.15 Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), 2022-2027

Table 7.16 IMLYGICRevenue Forecast: Revenue ($m), AGR (%), CAGR (%),2016-2021

Table 7.17 IMLYGICRevenue Forecast: Revenue ($m), AGR (%), CAGR (%),

Table 7.18 Gene Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%),2016-2021

Table 7.19 Gene Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%),2022-2027

Table 8.1 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2021

Table 8.2 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2027

Table 8.3 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share(%), 2016-2021

Table 8.4 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2022-2027

Table 8.5 European Biosimilar Approvals, 2006-2017

Table 8.6 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2016-2021

Table 8.7 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2022-2027

Table 8.8 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2016-2021

Table 8.9 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2022-2027

Table 8.10 BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2016-2021

Table 8.11 BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2022-2027